Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

NCT00239577
View directory record Official record
Conditions
Dengue
Interventions
Live attenuated tetravalent dengue vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects

NCT02006537
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2256294
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 29, 2026, 2:25 AM EDT
Recruiting No phase listed Observational

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

NCT01788839
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Interventions
surveys, Blood draw, Transvaginal ultrasounds
Behavioral · Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence

NCT04211831
View directory record Official record
Conditions
Overactive Bladder With Urge Urinary Incontinence
Interventions
URO-902, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
40 Years to 79 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects

NCT02136888
View directory record Official record
Conditions
Healthy
Interventions
Ponesimod Placebo, Moxifloxacin Placebo, Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg, Ponesimod 60 mg, Ponesimod 80 mg, Ponesimod 100 mg, Moxifloxacin 400 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 45 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 2 Interventional

Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen

NCT03373227
View directory record Official record
Conditions
Heart Transplant Rejection, Graft Failure, Compliance, Patient
Interventions
Envarsus
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 29, 2026, 2:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

NCT01107106
View directory record Official record
Conditions
Contraception
Interventions
ellaOne® (ulipristal acetate)
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
Female only
Enrollment
579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Denver, Colorado • Lakewood, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 29, 2026, 2:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

NCT07179614
View directory record Official record
Conditions
Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders
Interventions
Overdose Prevention Intervention Package (OPIP)
Behavioral
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Barbourville, Kentucky • Harlan, Kentucky • Hyden, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Text Messages Into the Mothers and Babies Course

NCT03420755
View directory record Official record
Conditions
Perinatal Depression, Postpartum Depression
Interventions
Mothers and Babies 1-on-1, Mothers and Babies Plus Text
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

NCT02139358
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Trastuzumab, Pertuzumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pelvic Floor Disorder Assessment of Knowledge and Symptoms: an Educational Model in Spanish-Speaking Women

NCT04829721
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urinary Incontinence, Patient Education
Interventions
Educational Intervention with video
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

NCT02176252
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

NCT01627587
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
GSK221149 750 mg, Ketoconazole, GSK221149 100 mg, GSK221149 750 mg Fasted, GSK221149 750 mg + Food
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

NCT03973047
View directory record Official record
Conditions
Nausea
Interventions
Bremelanotide, Zofran, Placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Compromised Microcirculation in Women With Polycystic Ovary Syndrome

NCT00757185
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
ganirelix acetate, methyl testosterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

NCT01093040
View directory record Official record
Conditions
Healthy
Interventions
CAT 354
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD7325 Multiple Ascending Dose Study

NCT00681915
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD7325
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

NCT01756417
View directory record Official record
Conditions
Healthy
Interventions
Metformin, Canagliflozin (JNJ-28431754)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

NCT04113668
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, diflunisal
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

NCT02080468
View directory record Official record
Conditions
Healthy
Interventions
lomitapide, EE/norgestimate
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of SQ109 in Healthy Adult Volunteers

NCT00866190
View directory record Official record
Conditions
TB Multi-drug Resistant
Interventions
SQ109, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Effects of Opioid Administration

NCT03801629
View directory record Official record
Conditions
Drug Effect
Interventions
High Morphine Dose, Low Morphine Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Relative Bioavailability Study

NCT01098513
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572 formulation AP, GSK1349572 formulation AW, GSK1349572 formulation AX
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 29, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013
View directory record Official record
Conditions
Obesity, Obese, Overweight or Obesity
Interventions
Bimagrumab, Semaglutide, Placebo
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 29, 2026, 2:25 AM EDT